Pembrolizumab (Keytruda) 100mg/4mL & 50mg | US FDA-Approved PD-1 Inhibitor | GLT
For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837
Generic Name: Pembrolizumab
Salt Name: Pembrolizumab (recombinant humanized anti-PD-1 monoclonal antibody)
Availability: On Request
Manufacturer: Merck Sharp & Dohme | United States
Strength: 50mg Lyophilized Powder / 100mg/4mL injection
What is Pembrolizumab (Keytruda)?
Pembrolizumab is a humanized monoclonal antibody that targets the PD-1 receptor on T-cells. By blocking the PD-1 immune checkpoint, it releases the brake on the immune system and enables T-cells to recognize and attack cancer cells. It is FDA-approved for the treatment of multiple advanced cancers and is one of the most widely used immuno-oncology agents worldwide.
What is Keytruda Used For?
Keytruda (pembrolizumab) is approved by the U.S. FDA for a broad range of indications including non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, renal cell carcinoma, endometrial carcinoma, and microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.
FDA-Approved Indications
The U.S. version of Keytruda is FDA-approved for multiple indications, including:
- Non-small cell lung cancer (NSCLC) — first-line and subsequent lines
- Melanoma — advanced and adjuvant treatment
- Head and neck squamous cell carcinoma (HNSCC)
- Classical Hodgkin lymphoma (cHL)
- Urothelial carcinoma
- Gastric and gastroesophageal junction adenocarcinoma
- Esophageal cancer
- Cervical cancer
- Hepatocellular carcinoma (HCC)
- Renal cell carcinoma (RCC)
- Endometrial carcinoma
- MSI-H / dMMR solid tumors
How Does Pembrolizumab Work?
PD-1 is a checkpoint protein on T-cells that normally keeps the immune response in check. Cancer cells often exploit PD-1 by expressing PD-L1, which binds to PD-1 and switches off the T-cell attack. Pembrolizumab binds to PD-1, preventing this interaction and restoring the immune system's ability to detect and destroy tumor cells.
Dosage & Administration
The recommended dose is 200 mg every 3 weeks or 400 mg every 6 weeks, administered as an intravenous infusion over 30 minutes. Keytruda is supplied as a 100 mg/4 mL (25 mg/mL) solution in a single-dose vial or as a 50 mg lyophilized powder for reconstitution. Dosing must be determined by the treating oncologist.
Common Side Effects
The most common adverse reactions (≥20%) include fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, and cough. Immune-related adverse events such as pneumonitis, colitis, hepatitis, and endocrinopathies may occur and require prompt medical attention.
Storage
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Do not shake. The lyophilized powder should be reconstituted and used per the manufacturer's instructions.
Why Choose the GLT?
The U.S. version is the reference product manufactured by Merck Sharp & Dohme. It offers the broadest FDA-approved label and is the most extensively studied pembrolizumab product globally.
Quality Assurance
All Keytruda supplied by GIVE LIFE TIME LIMITED is sourced from authorized channels with full batch traceability and Certificate of Analysis (COA). Every shipment includes export-ready documentation: commercial invoice, packing list, and Certificate of Origin.
How to Order
To request pricing and place an order, please follow these steps:
- Send your prescription or case file via WhatsApp or email — reviewed within 24 hours
- Receive a formal quotation with pricing, availability, and shipping options
- Confirm and arrange payment via bank transfer or PayPal
- Ship globally with full export documentation and tracking
Send your prescription / case file now: WhatsApp: +86 15234153837
Frequently Asked Questions
What is the difference between the 50mg powder and the 100mg/4mL solution?
Both contain the same active ingredient (pembrolizumab). The 50mg formulation is a lyophilized powder that requires reconstitution, while the 100mg/4mL is a ready-to-use solution. The appropriate form depends on the prescribing oncologist's protocol.
Is a prescription required?
Yes. Keytruda is a prescription-only medicine. A valid prescription from a licensed oncologist is required. Please send your prescription or case file via WhatsApp before ordering.
How long does international shipping take?
Most orders are dispatched within 3-5 business days after payment confirmation, with delivery times of 7-14 business days depending on destination and customs clearance.
Do you ship with cold-chain logistics?
Yes. Keytruda requires temperature-controlled shipping (2-8°C) and is packed in validated cold-chain packaging.